TTS Pharma Limited Announces Closing of £10.3 Million Fundraising and New Board Appointment
23.5.2019 09:00:00 EEST | Business Wire | Press release
COMPLETION OF SERIES B FUNDRAISE
TTS Pharma Limited (“TTS Pharma” or the “Company”), a UK company which is a vertically integrated supply chain manager in the cultivation, manufacturing and development of the emerging ethical cannabis market, announces that it has successfully closed a private equity investment totalling £10.3 million, on the basis of a two-tranche investment. This investment will permit TTS Pharma to become one of the leading global suppliers in this fast-growing multibillion-dollar industry, by allowing it to expand its existing supply chain, develop its own facilities and further strengthen its academic and commercial partnerships. It also enables the Company to advance its diversified operations in the wellness, nutraceutical and pharmaceutical sectors. The ethical cannabis market is set to become a high growth, disruptive and innovative new segment in the life sciences field and TTS Pharma is ideally positioned to capture rapid value within this market.
BOARD UPDATE
TTS Pharma also announces the appointment of a new Executive Chairman, Paul Atherton, who brings with him Global Institutional and Public Market experience to the board.
TTS Pharma is a unique business with core competencies and partners in drug discovery, development, separation, purification and drug delivery, incorporating the supply chain management of cannabinoids, such as CBD. It is intending to provide a transparent and accountable supply chain that produces legal and regulated cannabis-derived active agents for R&D, Bulk Active ingredients and wholesale distribution of finished goods. TTS Pharma is committed to producing the highest quality, fully compliant CBD products for use in a large range of commercial segments, alongside a number of partners, after obtaining the requisite regulatory clearance.
The pre-established supply chain including both domestic and international partners enables the Company to legally supply various CBD products to a growing range of customers. In mid-2018, TTS Pharma commenced a comprehensive R&D sponsorship programme to extract the various cannabinoids, and then to consider their chemical properties and effects, in order to develop new products in both human and animal markets.
Paul Atherton commented:
“I am delighted to join TTS Pharma as Executive Chairman. Utilising existing in-house know-how, TTS Pharma represents a unique chance to develop and produce world class, novel products for the rapidly growing new industry of ethically-based, legal cannabis products. I see a long-term opportunity to establish cost and scale advantages, allowing this Company to flourish in this attractive, global emerging industry.”
TTS Pharma CEO, Mark Tucker added:
“It is a great privilege to lead a team of highly experienced pharmaceutical professionals building an exciting portfolio of technologies and products based on world class expertise and industry leading know-how. We are well placed to build on the scientific developments driving this rapidly growing industry and provide cannabinoid products of unparalleled quality and consistency. Since my early involvement in pre-clinical cannabinoid trials in 2003, TTS Pharma has grown extensively and is now producing and developing a range of innovative and safe cannabis-based products within existing legislation and the evolving regulatory framework.”
About Paul Atherton
Paul Atherton was until the end of 2017, the Chief Executive Officer and Chief Financial Officer of Heritage Oil Limited, which held both production and exploration assets around the world. The company was one of the largest oil and gas companies listed on the Main Board of the London Stock Exchange and a member of the FTSE 250, before being taken private for US$1.6 billion in 2014. During this time Paul executed significant fundraisings, mergers and acquisitions and the eventual privatisation, generating outstanding shareholder returns. Paul is a Chartered Accountant having qualified at Deloitte and worked in corporate finance at BDO.
About TTS Pharma Ltd
TTS Pharma is a private company, incorporated in England and Wales and established in 2012, with offices in London and Liverpool. The Company has an R&D business developing products and holds deep industry expertise in extraction, separation and manufacturing of Cannabinoids. The Company has begun sales of its highly purified cannabis related products and technologies. The company abides by all legal and regulatory requirements in the UK and elsewhere and expects to gain further permissions related to these products in due course.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190522005683/en/
Contact information
Enquiries to:
TTS Pharma Ltd
Mark Tucker, CEO
mrtucker@ttspharma.com
Paul
Atherton, Chairman
patherton@ttspharma.com
Sciad
Communications Ltd
Maria Patey
TTSPharma@sciad.com
+44
203 7550571
Corporate Broker and Financial Advisor
The
Life Sciences Division Ltd
Ms Alia Minhas MBA ACSI
ali@thelifesciencesdivision.com
+44
207 8741890
Dr. Navid Malik. PhD, MSc, MBA, ACSI
navid@thelifesciencesdivision.com
+44
207 8741890
Legal Advisor
Osborne Clarke LLP
Dr
Janita Good, Partner Head of Lifescience and Healthcare
janita.good@osborneclarke.com
+44
207 1057042
M&A Advisor
ThinkingLinking
Mark
Dixon, Chief Thinking Officer
mdixon@thinkinglinking.com
+44
207 5561093
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samos Energy Acquisition Corporation Announces Pricing of Initial Public Offering10.7.2026 16:32:00 EEST | Press release
Samos Energy Acquisition Corporation (the “Company”) announced today the pricing of its initial public offering (“IPO”) of 20,000,000 units at a price of $10.00 per unit. The units will be listed on the New York Stock Exchange (the “NYSE”) and trade under the ticker symbol “SAMO.U” beginning on July 10, 2026. Each unit consists of one Class A ordinary share and one-half of one redeemable warrant, with each whole warrant entitling the holder thereof to purchase one of the Company’s Class A ordinary shares at an exercise price of $11.50 per share. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on the NYSE under the symbols “SAMO” and “SAMO.WS,” respectively. Cantor Fitzgerald & Co. is acting as the sole book running manager for the proposed offering. The Company has granted the underwriter a 45-day option to purchase up to an additional 3,000,000 units at the IPO price. The public offering is being made
Onera hPSG ® Wins Prestigious Red Dot Product Design Award10.7.2026 16:00:00 EEST | Press release
Onera Health, a leader in transforming sleep medicine, announces that its innovative product, Onera hPSG®, has been honoured with the prestigious Red Dot Product Design Award for 2026. This international recognition celebrates exceptional design quality and underscores Onera Health's commitment to excellence, creativity, and patient-centric innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260710266668/en/ Onera Health's patch-based home polysomnography solution, Onera hPSG®, wins Prestigious Red Dot Product Design Award 2026. The Red Dot Award, one of the most sought-after seals of quality for good design, attracted thousands of entries from around the globe. Onera hPSG® stood out for outstanding functionality, striking aesthetics, and thoughtful user experience. The expert jury praised the product for translating complex sleep diagnostics into a wearable, easy-to-use system that enables low-threshold application.
teamLab Biovortex Kyoto Welcomes Over 1 Million Visitors within 9 Months of Opening10.7.2026 10:00:00 EEST | Press release
teamLab Biovortex Kyoto has welcomed over 1 million visitors as of July 6, 2026, 9 months after its grand opening. (*1) These visitors arrived from more than 150 countries and regions. International visitors account for approximately 42% of the total. Many of these international visitors travel from distant countries and regions, including the United States, Australia, Canada, the United Kingdom, and Germany. Approximately 30% of these international visitors purchase their tickets at least 30 days in advance. teamLab Biovortex Kyoto is teamLab's largest museum in Japan, with an average visitor stay of over two and a half hours. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260709913938/en/ teamLab Biovortex Kyoto Welcomes Over 1 Million Visitors within 9 Months of Opening *1 According to ticket purchase data from the official teamLab Biovortex Kyoto website (survey period: October 7, 2025 – July 6, 2026) Visitors Comment (M
Robbyant Launches LingBot-VA 2.0 Built Natively for Embodied AI and Physical World Control10.7.2026 09:48:00 EEST | Press release
Robbyant, an embodied AI company within Ant Group, today announced the release of LingBot-VA 2.0, the industry’s first embodied-native video-action world model. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260709654440/en/ A robot powered by LingBot-VA 2.0 engages in a real-time tabletop air hockey match with a human This release marks a key transition in robotics foundation models, shifting from repurposing digital world models to designing them natively for the physical world. Instead of relying on fine-tuned digital content generation models, LingBot-VA 2.0 is built from scratch to meet the original demands of dynamic modeling, causal prediction, and real-time execution in physical environments. Integrating world models with embodied AI has been one of the major focuses of the AI industry. However, most mainstream approaches rely on video generation models designed for digital content, which are then fine-tuned for robo
SureWerx Appoints Erik Pertot as VP/GM SureWerx EMEA10.7.2026 09:00:00 EEST | Press release
SureWerx, a leading global manufacturer of personal protective equipment, safety products, tools and equipment solutions, today announced the appointment of Erik Pertot as VP/GM SureWerx EMEA. Pertot will report directly to CEO Scott Dowell and will lead growth, manufacturing and M&A activities in Europe across the company’s global portfolio. Erik joins SureWerx with more than 20 years of international leadership experience across engineering, quality, marketing, sales, international supply chain, product management, and general management. He brings deep expertise in the personal protective equipment industry, with a track record of leading complex, compliance-critical programs, managing business transitions, and driving growth across multinational environments. Most recently, Pertot served as Global General Manager for Footwear and Fall Protection at Protective Industrial Products (PIP), where he also held senior portfolio management leadership roles. Prior to that, he held a series
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom